SKN | Wells Fargo Highlights AMP-007 as Growth Driver for Amphastar Pharmaceuticals

Key Takeaways

• Wells Fargo lowered its price target on Amphastar Pharmaceuticals, Inc. to $30 from $34 while maintaining an Overweight rating.
• AMP-007 is viewed as critical to achieving mid- to high-single-digit revenue growth.
• The FDA approved Amphastar’s ANDA for Ipratropium Bromide HFA, granting 180 days of generic exclusivity.
• The approval strengthens Amphastar’s respiratory portfolio and near-term commercial positioning.

Target Cut but Growth Thesis Intact

Wells Fargo reduced its price target on Amphastar to $30 from $34, citing lower sales projections despite recent regulatory approvals for AMP-015 and AMP-007.

While shares have faced pressure, the firm maintained an Overweight rating, signaling continued confidence in the company’s longer-term revenue trajectory.

According to the analyst, AMP-007’s commercial execution will be central to delivering sustainable mid- to high-single-digit growth in the coming years.

FDA Approval Adds Near-Term Catalyst

On February 26, the U.S. Food and Drug Administration approved Amphastar’s Abbreviated New Drug Application for Ipratropium Bromide HFA Inhalation Aerosol, 17 mcg per actuation.

The agency determined the product to be medically and bioequivalent to Atrovent HFA from Boehringer Ingelheim.

As the first ANDA applicant with a Paragraph IV certification, Amphastar is entitled to 180 days of generic exclusivity beginning on the first commercial launch date. This temporary exclusivity window may support accelerated revenue capture and margin expansion in the respiratory category.

Strategic Importance of Respiratory Portfolio

The respiratory inhalation approval represents a significant regulatory milestone and aligns with Amphastar’s strategy of expanding its portfolio of complex generics and proprietary products.

The exclusivity period provides a short-term competitive advantage, potentially boosting early adoption rates while reinforcing the company’s presence in hospital and clinical markets.

The regulatory momentum also supports the company’s Q4 2025 performance narrative and enhances visibility into future product-driven growth.

Business Positioning

Amphastar develops, manufactures, and markets injectable, inhalation, and intranasal medications for hospitals and clinical use. Its portfolio focuses on critical care therapies and drug delivery innovation, targeting complex formulations that may carry higher barriers to entry.

The company’s ability to execute on pipeline launches and secure regulatory exclusivity periods remains central to its earnings outlook.

Outlook

While near-term sales guidance adjustments have weighed on sentiment, the combination of AMP-007 commercialization and new respiratory approvals could stabilize growth expectations.

Execution during the exclusivity window and sustained demand across core product lines will likely determine whether Amphastar achieves the projected mid- to high-single-digit revenue expansion.

For confidential discussions regarding small-cap pharmaceutical valuation models, ANDA exclusivity economics, product lifecycle management strategy, and portfolio positioning within specialty generics and respiratory therapeutics, our senior advisory team is available for discreet consultation tailored to institutional and cross-border mandates.